Four clusters were identified (severe persistent, moderate persistent, mild persistent, and fluctuating).
Asthma is classified based on the degree of symptom severity, which can be divided into four categories: mild intermittent, mild persistent, moderate persistent, and severe persistent.
Hence, a large "real-world" effectiveness study is needed to evaluate the benefits of early intervention with inhaled steroids in patients with mild, persistent asthma.
There is a need for further investigation into the true prevalence of mild persistent asthma in children and adolescents, and optimal treatment.
Limitations in asthma prevalence studies and difficulties in diagnosing pediatric asthma lead to uncertainty over the full extent of mild persistent asthma in children and adolescents.
It is unclear whether children with mild persistent asthma progress to more severe asthma, but the risk of severe asthma exacerbations seems to be unrelated to the symptom severity.
Therefore, we aimed to determine the efficacy of augmented Yu Ping Feng San (aYPFS) as an add-on to oral montelukast compared with montelukast alone for treatment of mild persistent asthma in children.
Clinical studies restricted to pediatric patients with mild asthma are limited, but available data do suggest substantial morbidity of mild persistent asthma in this population and support inhaled corticosteroid intervention.
Mild intermittent allergic rhinitis was found in 2.0% of patients, moderate to severe intermittent allergic rhinitis in 18.2% of patients, mild persistent allergic rhinitis in 5.6% of patients and moderate to severe persistent allergic rhinitis in 74.3% of patients.
The purpose of this study was to compare the efficacy and safety of the inhaled budesonide, sustained-release theophylline and montelukast, a leukotriene receptor antagonist, in patients with mild persistent asthma.
Most patients had moderate or severe COPD, and mild persistent or moderate persistent asthma.
